Drug likeness scoring and quantitative structure anaplastic lymphoma kinase (ALK) inhibitors activities relationships of pyrazolone derivatives

MakaleYalnız künyeScopus SJRQ3

Özet

Series of twenty-four compounds was the field for applying multi-parameter optimization (MPO) methods and qualitative approximations of structural activity relationships in order to determine the role of various physico-chemical and quantum descriptors used in QSAR modeling as independent variables. Anaplastic lymphoma kinase (ALK) inhibitory activity was considered as a component in this study. In order to illustrate the quantitative relationships between the molecular descriptors and the activity of pyrazolone derivatives, we have applied a multiple linear regression (MLR) procedure. By adopting cross-validation with the leave-one-out method, we could estimate the predictability of models. Our results suggest a QSAR model based on the following descriptors: S, V, LogP, POL, Ref, HOMO, LUMO, E, , HBA, PSA and NRB, for the inhibitory activities against ALK. Results show high correlation between experimental and predicted activity values, indicating the validation and the good quality of the QSAR model.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/12426Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1166/jbns.2018.1513Yayıncı resmi DOI adresi
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
0
OpenAlex
1
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorOuadah, Karim
dc.contributor.authorTchouar, Noureddine
dc.contributor.authorBelaidi, Salah
dc.contributor.authorOukil, Oualid
dc.contributor.authorCinar, Mehmet
dc.date.accessioned2026-10-29T19:09:34.156231131Z
dc.date.available2026-10-29T19:09:34.156231131Z
dc.date.issued2018
dc.description.abstractSeries of twenty-four compounds was the field for applying multi-parameter optimization (MPO) methods and qualitative approximations of structural activity relationships in order to determine the role of various physico-chemical and quantum descriptors used in QSAR modeling as independent variables. Anaplastic lymphoma kinase (ALK) inhibitory activity was considered as a component in this study. In order to illustrate the quantitative relationships between the molecular descriptors and the activity of pyrazolone derivatives, we have applied a multiple linear regression (MLR) procedure. By adopting cross-validation with the leave-one-out method, we could estimate the predictability of models. Our results suggest a QSAR model based on the following descriptors: S, V, LogP, POL, Ref, HOMO, LUMO, E, , HBA, PSA and NRB, for the inhibitory activities against ALK. Results show high correlation between experimental and predicted activity values, indicating the validation and the good quality of the QSAR model.
dc.identifier.doi10.1166/jbns.2018.1513
dc.identifier.endpage259
dc.identifier.issn1557-7910
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85049147588
dc.identifier.startpage250
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/12426
dc.identifier.volume12
dc.language.isoen
dc.publisherAmerican Scientific Publishers
dc.relation.ispartofJournal of Bionanoscience
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectALK
dc.subjectMLR
dc.subjectPyrazolone
dc.subjectQSAR
dc.subjectSAR/SPR
dc.subject.otherEnzymes
dc.subject.otherLinear regression
dc.subject.otherMolecular graphics
dc.subject.otherOncology
dc.subject.otherAnaplastic lymphoma kinase
dc.subject.otherLeave one out methods
dc.subject.otherMulti-parameter optimizations
dc.subject.otherMultiple linear regressions
dc.subject.otherPyrazolones
dc.subject.otherQSAR
dc.subject.otherQuantitative structures
dc.subject.otherSAR/SPR
dc.subject.otherComputational chemistry
dc.titleDrug likeness scoring and quantitative structure anaplastic lymphoma kinase (ALK) inhibitors activities relationships of pyrazolone derivatives
dc.typeArticle
rdl.citation.openalex1
rdl.citation.scopus0
rdl.oa.statusclosed
rdl.scopus.quartileQ3
rdl.source.indexSCOPUS